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Yclopidogrel-treated patients undergoing emergent or elective PCI for stable angina or
acute coronary syndrome (non-ST-elevation and ST-elevation myocardial infarction,
unstable angina). The main outcome measures were cardiovascular (CV) death, def-
inite/probable stent thrombosis (ST), nonfatal myocardial infarction (MI), coronary
revascularization (PCI or CABG) and a composite end point of ischemic events. High
platelet reactivity (HPR) was deﬁned as PRU (P2Y12 Reaction Unit) value  240 or 252.
RESULTS In total, 1038 consecutive patients were enrolled (Male 749, 72.7%). Pa-
tients with HPR were 487 (46.9%). VerifyNow P2Y12 cartridge was used in 1038 pa-
tients. All patients received optimal clopidogrel pretreatment and maintenance
therapy. At a 12-month follow-up, we found 85 ischemic events (18 CV deaths [1.7%],
7 nonfatal MIs [0.7%]), 5 stent thrombosis (0.5%) and 47 target-vessel re-
vascularizations (4.5%). The CV rate of patients with HPR (PRU > 240) was signiﬁ-
cantly higher rate (2.7% vs 1.0% (p ¼ 0.030)) than the patients with normal value. The
composite end point event rate of patients with HPR (PRU > 240) was also signiﬁ-
cantly higher rate (8.07% vs 4.5% (p ¼ 0.020)) than the patients with normal value. In
survival analysis, there was no signiﬁcant difference between patient with HPR (PRU
> 240) and normal reactivity. But between patient with HPR (PRU > 252, cutoff value
of CILON-T trial) and normal reactivity, the survival rate free from the CV death was
signiﬁcantly lower in patients with high on-treatment platelet reactivity(p ¼ 0.037,
Log Rank test).
CONCLUSION HPR tested by VerifyNow predict coronary adverse event in patients
after PCI. In Korean, the rate of HPR was higher than western people and we seem to
have to raise the optimal cutoff value of PRU to predict future coronary event in
Korean.
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Assessment Of Impact Of Chronic Kidney Disease On Platelet Inhibition Among
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BACKGROUND CKD may inﬂuence the response to antiplatelet therapy. We, there-
fore, sought to investigate its effect on platelet inhibition according to its stages.
METHODS We assessed platelet inhibition (PI) among those patients on dual anti-
platelet regimen (75 mg of Aspirin and 75 mg of clopidogrel) in various stages of CKD
in 922 patients after PCI with stent implantation. Platelet inhibition was tested with
platelet aggregometry. Effective PI is deﬁned as > 50% platelet inhibition. CKD was
deﬁned as a estimated glomerular ﬁltration rate (eGFR) <60 mL/min/1.73 m2 . eGFR
was estimated by MDRD formula. We analyzed PI levels with eGFR values using
Pearson correlation test.
RESULTS Total no of cases are 922. Male:female::3.4:1. 606 (66%) were hyperten-
sives, 417 (45%) were diabetics and 224 (24%) were smokers. 548 (59%) pts were
presented with ACS and multi vessel angioplasty was done in 214 (23%) patients.
Total no of lesions treated were 1225 in 922 pts . Prevalence of patients according
to stages of CKD were - Stage 1 - 209(23%); Stage 2 - 415 45(%);Stage 3a - 158 (17%);
Stage 3b - 104 (11%); Stage 4 - 15 (1.6%); Stage 5 - 19(2%) pts. There was no correlation
between estimated GFR and percentage of inhibition of platelets in all pts (Pearson
correlation ¼ -0.021; p Value ¼ 0.7) and in different stages CKD pts (Stage 1 -
Pearson correlation ¼ -0.039, p value ¼ 0.8, Stage 2 - correlation ¼ -0.008, p ¼ 0.9,
Stage 3a correlation ¼ -0.002, p ¼ 0.98, Stage 3b correlation ¼ 0.052, p ¼ 0.8, Stage 4
correlation ¼ 0.9, p ¼ 0.1 and Stage 5 correlation ¼ -0.6, p ¼ 0.3) .
CONCLUSION Presence of CKD (including the all stages) does not inﬂuence the
effectiveness of platelet inhibition with antiplatelet therapy in pts undergoing PCI for
obstructive CAD.ATHERECTOMY DEVICES
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Safety of Rotational Atherectomy in High Risk PCI with Hemodynamic Support
Soha Ahmad, Han Tun, Michael Gaglia, Anilkumar Mehra, Ray V. Matthews,
David M. Shavelle, Leonardo Clavijo
University of Southern California, Los Angeles, CA
BACKGROUND Rotational atherectomy (RA) can aid in high risk Percutaneous Coro-
nary Intervention (PCI) with hemodynamic support. There is concern that use of RA
could result in increased procedural complications. We report our institution’s
experience with RA in high risk PCI with hemodynamic support.
METHODS 398 patients underwent high risk PCI with intraaortic balloon pump (IABP)
(n¼327), Impella (n¼57), or Tandem Heart (n¼14) between 2008 and July 2014.
Patients with ST elevated myocardial infarction were excluded (n¼129). Patients who
underwent RA (n¼34) were compared to those who did not (n¼235). Among the 34
patients who underwent RA, Impella use (n¼10) versus IABP use (n¼23) was
compared.
RESULTS Patients in the RA arm were older (71.9114.47 vs. 64.7712.63, p¼0.003)
and less likely in cardiogenic shock (6% vs. 23%, p¼0.02). There was no difference inthe number of diseased vessels (RA¼ 2.860.88 vs. no RA ¼2.680.99, p¼NS),
location of vessels, or number of total occlusions (RA ¼ 32% vs. no RA ¼32%, p¼NS).
PCI without stent deployment was less common in the RA arm (15% vs. 37%, p¼0.01).
There was no difference in stent diameter or length. There was a trend toward more
Impella use, but this was not statistically different (RA ¼ 29% vs. no RA ¼18%, p¼NS).
There was no difference in morbidity, hospital mortality, recurrent MI, or repeat
revascularization. Within the rotational atherectomy group, there was no difference
in outcome between IABP or Impella 2.5.
CONCLUSION In our center’s experience, use of rotational atherectomy in high risk
PCI with hemodynamic support is feasible and not associated with increased
morbidity or mortality.CRT-129
One-year Safety Outcomes In Diabetic Patients Treated With Orbital
Atherectomy For De Novo, Severely Calciﬁed Coronary Lesions: A Sub-analysis
Of The ORBIT II Trial
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BACKGROUND Patients with diabetes mellitus (DM) are at increased risk for severe
coronary artery calciﬁcation. Severely calciﬁed lesions make successful balloon an-
gioplasty and stent delivery more difﬁcult during percutaneous coronary interven-
tion (PCI) and treatment may lead to serious procedural complications. Compared to
non-diabetics, diabetics have increased incidence of major adverse cardiac events
(MACE) after PCI. In this analysis, we compared 1-year safety outcomes in ORBIT II
patients with or without DM treated with the Diamondback 360 Coronary Orbital
Atherectomy System (OAS) (Cardiovascular Systems, Inc., St. Paul, MN).
METHODS ORBIT II, a prospective, multi-center trial conducted in the US, was
designed to evaluate the safety and efﬁcacy of the Diamondback 360 Coronary OAS to
prepare de novo, severely calciﬁed coronary lesions for stent deployment. Freedom
from 1-year MACE (deﬁned as cardiac death, myocardial infarction (MI, CK-MB>3X
ULN), and target vessel revascularization (TVR)) was compared in patients with his-
tory of DM (DM group, N¼160) versus patients without history of DM (no-DM group,
N¼283).
RESULTS Patients in the DM group were younger (70.3  0.7 vs 72.0  0.6, p¼0.02),
had higher BMI (31.0  0.5 vs 28.5  0.3, p<0.0001), higher prevalence of hyperten-
sion (96.3% vs 89.0%, p¼0.01), and higher rate of previous coronary artery bypass
graft (20.0% vs 11.7%, p¼0.02). As estimated by Kaplan-Meier, at one one-year both
DM and non-DM patients had similar high freedom from MACE (83.5% vs 83.6%,
